Danaher Corporation $DHR Shares Sold by Aspiriant LLC

Aspiriant LLC lowered its stake in shares of Danaher Corporation (NYSE:DHR) by 4.5% in the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 4,594 shares of the conglomerate’s stock after selling 216 shares during the period. Aspiriant LLC’s holdings in Danaher were worth $908,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors also recently bought and sold shares of the company. Nuveen LLC acquired a new stake in shares of Danaher in the first quarter worth approximately $833,941,000. Invesco Ltd. boosted its stake in Danaher by 44.5% during the 1st quarter. Invesco Ltd. now owns 4,708,578 shares of the conglomerate’s stock worth $965,259,000 after purchasing an additional 1,450,703 shares during the last quarter. Baird Financial Group Inc. boosted its stake in Danaher by 290.6% during the 1st quarter. Baird Financial Group Inc. now owns 1,441,706 shares of the conglomerate’s stock worth $295,550,000 after purchasing an additional 1,072,617 shares during the last quarter. Generation Investment Management LLP grew its holdings in shares of Danaher by 33.2% during the first quarter. Generation Investment Management LLP now owns 3,178,124 shares of the conglomerate’s stock worth $651,515,000 after buying an additional 791,662 shares in the last quarter. Finally, Parnassus Investments LLC raised its position in shares of Danaher by 23.3% in the first quarter. Parnassus Investments LLC now owns 3,828,024 shares of the conglomerate’s stock valued at $784,745,000 after buying an additional 722,636 shares during the last quarter. 79.05% of the stock is currently owned by institutional investors and hedge funds.

Danaher Price Performance

DHR stock opened at $209.14 on Friday. Danaher Corporation has a 52-week low of $171.00 and a 52-week high of $275.51. The company has a quick ratio of 1.22, a current ratio of 1.62 and a debt-to-equity ratio of 0.32. The stock has a market cap of $149.76 billion, a price-to-earnings ratio of 44.50, a price-to-earnings-growth ratio of 2.98 and a beta of 0.77. The business has a fifty day moving average of $201.60 and a two-hundred day moving average of $197.24.

Danaher (NYSE:DHR) last released its quarterly earnings results on Tuesday, July 22nd. The conglomerate reported $1.80 earnings per share for the quarter, topping analysts’ consensus estimates of $1.64 by $0.16. The business had revenue of $5.94 billion during the quarter, compared to analysts’ expectations of $5.83 billion. Danaher had a return on equity of 10.70% and a net margin of 14.21%.The company’s revenue was up 3.4% compared to the same quarter last year. During the same period in the prior year, the business posted $1.72 EPS. Danaher has set its FY 2025 guidance at 7.700-7.800 EPS. As a group, research analysts anticipate that Danaher Corporation will post 7.63 earnings per share for the current year.

Danaher Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, October 31st. Stockholders of record on Friday, September 26th will be paid a $0.32 dividend. This represents a $1.28 dividend on an annualized basis and a dividend yield of 0.6%. The ex-dividend date of this dividend is Friday, September 26th. Danaher’s payout ratio is 27.23%.

Insider Activity at Danaher

In related news, Director Teri List sold 2,778 shares of the stock in a transaction that occurred on Friday, August 22nd. The shares were sold at an average price of $211.06, for a total transaction of $586,324.68. Following the completion of the transaction, the director owned 20,751 shares of the company’s stock, valued at approximately $4,379,706.06. This trade represents a 11.81% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Corporate insiders own 11.10% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages recently issued reports on DHR. Wall Street Zen raised shares of Danaher from a “hold” rating to a “buy” rating in a research note on Friday, June 27th. Guggenheim restated a “buy” rating and issued a $250.00 price target on shares of Danaher in a research report on Wednesday, July 23rd. Rothschild & Co Redburn reiterated a “neutral” rating and set a $220.00 price objective (down previously from $245.00) on shares of Danaher in a research report on Wednesday, October 8th. Barclays restated an “overweight” rating and issued a $225.00 target price (up from $215.00) on shares of Danaher in a report on Tuesday, June 24th. Finally, UBS Group cut their target price on Danaher from $240.00 to $225.00 and set a “buy” rating for the company in a research note on Wednesday, July 23rd. Seventeen analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $245.00.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.